ID: MRFR/Pharma/3824-HCR | 90 Pages | Published By Rahul Gotadki on March 2023
Cone-Rod Dystrophy is a group of related eye disorders that cause gradual loss of vision due to retinal deterioration this may lead to increasing severity or even blindness. Generally, the disorders affects the rod and cones cells present in the retina which are responsible for vision and clarity. According to NCBI, prevalence of cone-rod dystrophies is estimated to be 1 in every 40,000 cases.
According to World Health Organization, in 2014, worldwide 285 million people were estimated to be visually impaired, out of which nearly 246 million have low vision and 39 million are completely blind. Uncorrected errors are the major reasons for causing moderate and severe visual impairment. But still, 80% of the ophthalmic diseases can be cured or prevented by treatment.
There are many new low vision aids, including telescopic and magnifying lenses, providing plenty of choice for users at all stages of sight loss. This technology has also removed many barriers to education and employment. According to American Academy of Ophthalmology, more than 25% of America’s population suffer from minor or major visual complication. More than 150 million Americans use corrective eyewear and spend more than $15 billion each year on eyewear.
Ophthalmic impairment is caused due to a number of diseases like infectious diseases, genetic factor and many more, but diabetes have a major impact on the growth of the Cone-rod dystrophy Market. Diabetes is one of the important disorder responsible for causing visual impairment as it damages retinal blood vessels. According to WHO, 422 million people are suffering from diabetes and this number is increasing at the rate of 8.5%. According to the American Academy of Ophthalmology, diabetes is responsible for causing visual complication in approximately 4.5 million Americans.
This disorder can be curbed to a great extent by proper use of vitamin supplements therefore the cone rod dystrophy market is majorly effected by the Thiamine supplements. The growth of the vitamin industry is due to the increased per-capita income and increased health awareness among people. As the people are getting more aware about taking care of their health, they are giving more importance to these supplements to prevent various deficiencies. Online retailing of these supplements has further increased accessibility and has increased the customer base and it has also increased the convenience of buying which will indirectly effect the Cone-rod dystrophy Market.
Despite the lack of current treatments for cone-rod dystrophies, general eye check-ups are important. Furthermore, the people suffering from this conditions may experience other kinds of eye problems. Patients with cone rod dystrophy tend to develop cataracts at an earlier age as compared to the unaffected population.
Currently, there is no treatment to stop a person with Cone Rod Dystrophy (CRD) from losing their vision. Possible future treatments for CRD may include gene therapy, stem cell therapy, and retinal implants. The beta-carotenoids, lutein and zeaxanthin, have been evidenced to reduce the risk of developing to Cone dystrophy sufferers.
The Cone-Rod Dystrophy Market is expected to grow at a CAGR of approximately 5.3% during the forecast period 2017-2023.
Some of key the players in the cone-rod dystrophy market are GlaxoSmithKline Plc. (U.S.), Johnson & Johnson (U.S.), Sanofi (Switzerland), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories (U.S.), Sunovion Pharmaceuticals (U.S.), Cephalon (U.S.), DSM (India), Amway (U.S.), Vitamin Shoppe (U.S.), Intas Pharmaceutials Limited (India), Sun Pharmaceuticals Ltd. (India) Emcure Pharmaceuticals Limited (India), Nutrilite (U.S.), NutraScience Labs (U.S.), and others.
Sources: Annual reports, Press release, White paper, and Company presentation
The Cone-rod dystrophy Market is segmented on the basis of diagnosis, treatment, and end-users.
On the basis of the diagnosis, the Cone-rod dystrophy Market is segmented into electroretinogram (ERG), clinical history, fundus examination, molecular diagnosis, and others.
On the basis of the treatment, the Cone-rod dystrophy Market is segmented into tinted lenses/ dark sunglass, medications, magnifying devices, and surgery. The medication is classified into vitamin A supplement and anticonvulsant.
On the basis of the end-user, the Cone-rod dystrophy Market is segmented into hospitals, ophthalmic centers, research organizations, and academic institutes.
The cone-rod dystrophy market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is projected to hold the largest share of the global cone rod dystrophy market due to the increasing eye disorders in the U.S. According to American Academy of Ophthalmology, over 10 million laser eye surgery procedures are performed in the U.S. each year with a satisfaction rate of 95.4%. Majority of people prefer ophthalmic clinics rather than hospitals. Besides this, increasing number of ophthalmic clinics across the globe has led to increase the market. According to the International Council of Ophthalmology, there are approximately 213,459 ophthalmologists worldwide of which around 19,216 are present in the U.S.
The European region is expected to be the second largest market over the forecast period owing to substantial technological advancements. According to the National Organization for Rare Disorders (NORD), the estimated incidence of the disorder is approximately 1 in 30,000 individuals in the general population. Cone dystrophy is usually present in early infancy or during childhood or early adulthood. However, the disorder has been reported to develop in individuals of all ages including older adults.
The Cone-rod dystrophy Market in the Asia Pacific is expected to witness the fastest growth rate within the forecast period due to increasing geriatric population coupled with rising cases of ocular genetic disorders. The Middle East and Africa are also expected to grow considerably less over the forecast period.
The cone rod dystrophy market projected to grow at a 5.3% CAGR between 2018-2023.
The Americas is expected to dominate the cone rod dystrophy market.
Major end users of the cone rod dystrophy market include academic institutes, research organizations, ophthalmic centers, and hospitals.
Key players profiled in the cone rod dystrophy market include NutraScience Labs (U.S.), Nutrilite (U.S.), Emcure Pharmaceuticals Limited (India), Sun Pharmaceuticals Ltd. (India), Intas Pharmaceutials Limited (India), Vitamin Shoppe (U.S.), Amway (U.S.), DSM (India), Cephalon (U.S.), Sunovion Pharmaceuticals (U.S.), Abbott Laboratories (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi (Switzerland), Johnson & Johnson (U.S.), and GlaxoSmithKline Plc (U.S.).
Strategies adopted by key players to stay ahead in the cone rod dystrophy market include strategic alliances, joint ventures, new product launches, and acquisitions.